A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

Inclusion Criteria:

• Participant must have histologically or cytologically confirmed NSCLC and must havemetastatic NSCLC at the time of enrollment

• Participant must have at least 1 measurable lesion, according to RECIST v1.1, thathas not been previously irradiated

• May have brain metastases only if previously definitively treated, and participantis clinically stable and asymptomatic for >2 weeks and is off or receiving low-dosecorticosteroid treatment (<=10 mg prednisone or equivalent) for at least 2 weeksprior to start of study treatment

• May have a prior malignancy (other than the disease under study) if the naturalhistory or treatment is unlikely to interfere with any study endpoints of safety orthe efficacy of the study treatment(s)

• Have an ECOG performance status of 0 or 1

Exclusion Criteria:

• For Phase 2 only: Participant has known oncogenic driver mutations (EGFR, MET, HER2,ALK, ROS1, NTRK, BRAF, RET, or KRAS) as detected by local testing or by centralctDNA testing

• Participant has received radiotherapy for palliative purposes less than 14 daysprior to the first dose of study treatment

• Participant has: a.(Or has a history of) leptomeningeal disease (carcinomatousmeningitis); b. Spinal cord compression not definitively treated with surgery orradiation.

• Medical history of (non-infectious) ILD/pneumonitis, or has current ILD/pneumonitis,or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening-Participant has history of any significant drug allergy (such as anaphylaxis,hepatotoxicity, or immune-mediated thrombocytopenia or anemia) or has knownallergies, hypersensitivity, or intolerance to: a. amivantamab or amivantamabexcipients (refer to the amivantamab IB); b.docetaxel, docetaxel excipients or toother drugs formulated with polysorbate and paclitaxel